Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Anika Therapeutics (ANIK) Leases (2016 - 2026)

Anika Therapeutics has reported Leases over the past 14 years, most recently at $25.4 million for Q1 2026.

  • Quarterly Leases rose 0.99% to $25.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $25.4 million through Mar 2026, up 0.99% year-over-year, with the annual reading at $25.9 million for FY2025, 0.99% up from the prior year.
  • Leases was $25.4 million for Q1 2026 at Anika Therapeutics, down from $25.9 million in the prior quarter.
  • Over five years, Leases peaked at $31.6 million in Q2 2022 and troughed at $20.5 million in Q1 2022.
  • The 5-year median for Leases is $27.6 million (2023), against an average of $27.3 million.
  • Year-over-year, Leases soared 47.07% in 2023 and then fell 10.96% in 2025.
  • A 5-year view of Leases shows it stood at $30.7 million in 2022, then fell by 10.24% to $27.6 million in 2023, then fell by 6.78% to $25.7 million in 2024, then grew by 0.99% to $25.9 million in 2025, then dropped by 1.96% to $25.4 million in 2026.
  • Per Business Quant, the three most recent readings for ANIK's Leases are $25.4 million (Q1 2026), $25.9 million (Q4 2025), and $24.2 million (Q3 2025).